Bausch Health Companies Inc. (NYSE:BHC) previous close was $29.79 while the outstanding shares total 356.80M. The firm has a beta of 1.71. BHC’s shares traded lower over the last trading session, losing -1.61% on 06/18/21. The shares fell to a low of $28.965 before closing at $29.31. Intraday shares traded counted 3.52 million, which was -23.81% lower than its 30-day average trading volume of 2.84M. The stock’s Relative Strength Index (RSI) is 36.31, with weekly volatility at 2.98% and ATR at 0.82. The BHC stock’s 52-week price range has touched low of $14.86 and a $34.80 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Bausch Health Companies Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $10.67 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Bausch Health Companies Inc. (BHC) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 5.39 billion total, with 4.9 billion as their total liabilities.
BHC were able to record 377.0 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 131.0 million. In cash movements, the company had a total of 443.0 million as operating cash flow.
Potential earnings growth for Bausch Health Companies Inc. (BHC)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Bausch Health Companies Inc. recorded a total of 2.03 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.74% coming in sequential stages and their sales for the 08/10/2021 quarter reducing by -9.18%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 574.0 million trying to sell their products during the last quarter, with the result yielding a gross income of 1.45 billion. This allows shareholders to hold on to 356.80M with the recently reported earning now reading -1.70 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (1.04 cents a share).
Having a look at the company’s valuation, the company is expected to record 4.75 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BHC sounds very interesting.
Is the stock of BHC attractive?
In related news, EVP & Chief Financial Officer, Eldessouky Sam sold 17,000 shares of the company’s stock in a transaction that recorded on Jun 11. The sale was performed at an average price of 31.68, for a total value of 538,586. As the sale deal closes, the EVP AND GENERAL COUNSEL, ACKERMANN CHRISTINA now sold 121,198 shares of the company’s stock, valued at 3,857,732. Also, Director, WECHSLER AMY B sold 11,037 shares of the company’s stock in a deal that was recorded on May 26. The shares were price at an average price of 31.79 per share, with a total market value of 350,811. Following this completion of acquisition, the President, Ortho-Dermatologics, Humphries William D. now holds 114,055 shares of the company’s stock, valued at 2,266,398. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.30%.
10 out of 16 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Bausch Health Companies Inc.. 0 analysts has assigned a Sell rating on the BHC stock. The 12-month mean consensus price target for the company’s shares has been set at $35.33.